| Alnylam Pharmaceuticals is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today. Alnylam scientists and management will be joined by two guest speakers: Professor Allan Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus infection in the lung transplant patient population; and Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School, Royal Free Hospital, will discuss transthyretin-mediated amyloidosis. Alnylam is developing RNAi therapeutics for the treatment of both RSV infection and ATTR, amongst other pipeline programs. :theflyonthewall.com |
